The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

Mini reviews in medicinal chemistry

Volumn 3, Issue 3, 2003, Pages 257-270

  Zheleva, Daniella I ^a   Lane, David P ^a   Fischer, Peter M ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN BINDING; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; GENE THERAPY; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038699629     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557033488178     Document Type: Review

References (183)